Non-Small Cell Lung Cancer Coverage from Every Angle

Recent News

FDA Brief: Cemiplimab-rwlc Accepted for Review in First-Line Combination Therapy for Advanced Lung Cancer
Potential Correlation Between Stage Shift and Survival Among Patients With NSCLC
ZENITH20 Trial: Poziotinib in NSCLC After Prior Therapies
Global Study of Sequential Afatinib and Osimertinib in EGFR Mutation–Positive NSCLC
FDA Brief: Novel EGFR Inhibitor Granted Breakthrough Therapy Designation in Lung Cancer
Anti-TIGIT Monoclonal Antibody Plus Pembrolizumab Focus of Phase II Study in NSCLC
Biomarker-Directed Analysis of First-Line Pembrolizumab-Based Therapies in NSCLC
Tumor Biopsy Analysis of Anticancer Vaccine–Treated Patients With Advanced NSCLC
Chemoradiation Plus Pembrolizumab for Locally Advanced NSCLC
Survival Rates for Lung Cancer: Increasing but Still Lower in People of Color
SITC 2021: Early-Phase Study Results of LN-145 Monotherapy in NSCLC
Stereotactic Body Radiation Therapy and Primary Tumor Control in NSCLC
SITC 2021: Prevalence of KRAS mutations in Advanced Nonsquamous NSCLC
SITC 2021: Immunomodulatory Effects of Neoadjuvant Nivolumab and Chemotherapy in NSCLC
How Does Ensartinib Compare With Crizotinib in First-Line Treatment of ALK-Positive NSCLC?
FDA Brief: Bemcentinib Combination Given Fast Track Status for STK11-Altered Advanced Lung Cancer
Immunotherapy Plus Chemoradiation Followed by Nivolumab Maintenance in Unresectable NSCLC
High-Dose Osimertinib in EGFR Exon 20 Mutation–Positive Lung Cancer
Can Telemedicine Lung Cancer Screening Expand Access to Screening?
Consolidation Durvalumab After Chemoradiotherapy in a Real-World Cohort With NSCLC
Can Inflammation Score Predict Effect of Tislelizumab in Squamous NSCLC?
ASTRO 2021: Targeted Radiation Therapy for Oligoprogressive Metastatic Lung Cancers
ASTRO 2021: Can PD-L1 Expression Predict Outcomes in Unresectable Stage 3 NSCLC?
Pembrolizumab and Chemotherapy for Patients With EGFR- or ALK-Positive NSCLC
Spectrum-Selective Tyrosine Kinase Inhibitor Plus Nivolumab Under Study in NSCLC
TROPION-Lung04 Examines New Antibody-Drug Conjugate in Combination Therapy
Osimertinib After Progression of Advanced NSCLC Under Study in COMPEL Trial
Episodic Dyspnea in Patients With Advanced Lung Cancer: International Update
COVID-19 and NSCLC: Adapted Versus Standard Dose Schedule for Immunotherapies
FDA Grants Approval to Atezolizumab for Adjuvant Treatment of NSCLC
ESMO 2021: GEMSTONE-301 Trial of Novel PD-L1 Inhibitor in Unresectable Stage III NSCLC
CheckMate 9LA: Dual Immunotherapy Plus Chemotherapy for Patients With NSCLC and Brain Metastases
ESMO 2021: Novel Antibody-Drug Conjugate Under Study in Advanced Lung Cancer
ESMO 2021: Anticancer Vaccine Under Study in HLA-A2–Positive Lung Cancer
ESMO 2021: Bevacizumab Versus the Biosimilar MIL60 in Nonsquamous NSCLC
IASLC 2021: Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant NSCLC
ESMO 2021: Use of Poziotinib for NSCLC Harboring HER2 Exon 20 Mutations Under Study
ESMO 2021: Patterns of Relapse From IMpower010 of Atezolizumab Versus Best Supportive Care in NSCLC
IASLC 2021: Disparities in Lung Cancer Care
ESMO 2021: Primary Results From DESTINY-Lung01 on T-DXd in HER2-Mutated Lung Cancer
IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC
ESMO 2021: Durvalumab-Based Combinations in COAST Trial of Locally Advanced NSCLC
IASLC 2021: CheckMate 907 on De Novo Administration of Nivolumab in Advanced NSCLC
FDA Approves Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations
IASLC 2021: Antibody Response to SARS–CoV-2 Vaccination in Patients With Lung Cancer
IASLC 2021: POSEIDON Trial of Durvalumab Plus Tremelimumab in Metastatic NSCLC
Chemotherapy and Immunotherapy for KEAP1/NFE2L2-Mutant Lung Cancer
Autologous Tumor-Infiltrating Lymphocyte Treatment Under Study in Metastatic NSCLC
Amivantamb Under Study in Treatment of EGFR Exon 20 Insertion–Mutated NSCLC
Does Antibiotic Therapy Impact Outcomes to Chemoimmunotherapy in NSCLC?
TP53-Mutated Non–Small Cell Lung Cancer and Airborne Pollutants
Does the Use of Metformin Improve Outcomes in Patients With Non–Small Cell Lung Cancer?
IASLC Consensus Statement on Liquid Biopsy for Patients With Advanced NSCLC
Atezolizumab Receives Priority Review From the FDA in Early NSCLC
PET/CT Images: Measuring PD-L1 Status and Predicting Response to Immunotherapy in NSCLC
Can Postoperative Radiotherapy Improve Survival Outcomes in Patients With NSCLC?
Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.